Acquisition of Belgium-based Custodix Promises to Bring New Pharmaceutical-Sponsored Clinical Trials to Healthcare Organizations Throughout Europe
Cambridge, MA, April 2, 2019 — TriNetX, Inc., the global health research network that revolutionizes clinical research and enables discoveries through the generation of real-world evidence (RWE), today announced the acquisition of Custodix NV and its InSite network, a European-based provider of services for clinical trial design, patient feasibility, and enabling workflow for patient recruitment. The financial details of the transaction were not disclosed.
Custodix’s InSite network is active in 12 countries throughout Europe and complements the existing TriNetX European footprint. In addition to the US and Europe, TriNetX is powered by an impressive network of healthcare organizations (HCOs) globally, including Japan, Singapore, Malaysia, Philippines, India, Israel, and Brazil.
The acquisition comes following TriNetX’s recent Series D funding raised in part to support the company’s international expansion. The unity establishes the largest research network in Europe and presents existing InSite healthcare organizations with increased access to clinical trial opportunities. TriNetX’s customer base includes 29 industry partners, consisting of 11 of the largest pharmaceutical companies including Novartis, Sanofi and Pfizer, and top contract research organizations (CROs) including Syneos and ICON. TriNetX has been used to analyze over 13,000 protocols and has presented over 3,400 trial opportunities to its HCO members.
“This is a breathtaking unification of two extremely compatible research networks,” said Gadi Lachman, TriNetX CEO. “The two companies launched in separate geographies, but share a commitment to strong compliance, governance, and a global vision for clinical research. We now offer the world’s largest platform for clinical research, providing a more powerful resource for pharma companies and healthcare organizations, and more hope for patients in need. This expansion gives us additional local leadership, regional support, and increased resources in the European market.”
The Custodix addition quadruples the size of the current European TriNetX staff and establishes an EU headquarters as a resource base to launch further expansion in Europe and Asia. Custodix’s CEO Brecht Claerhout will become TriNetX’s Managing Director/Europe and the division—to be known as InSite, a TriNetX company—will drive the combined organization’s European strategy and execution going forward.
“This deal is exciting news for the healthcare organizations in our InSite network,” said Brecht Claerhout. “We share similar values to TriNetX, which will enable us to continue collaborating with the hospital community, service our customer base as we always have, and bring new clinical trial opportunities to researchers and their patients.”
The InSite platform is an initiative of Custodix that was named one of the most promising SME health initiatives in 2016 by the European Commission and in 2018, received the Clinical Informatics News European Innovation Award. InSite builds on the outcome of several international research projects and in collaboration with the pharmaceutical industry through the EHR4CR project as part of the Innovative Medicines Initiative (IMI) research program.
TriNetX is the global health research network that revolutionizes clinical research and enables discoveries through the generation of real-world evidence. TriNetX combines real time access to longitudinal clinical data with state-of-the-art analytics to answer complex research questions at the speed of thought. The TriNetX platform is HIPAA and GDPR compliant. For more information, visit TriNetX at https://trinetx.com/ or follow @TriNetX on Twitter.
InSite is a private initiative determined to define and realize a sustainable eco-system for real-world data-driven clinical trial design and execution. InSite is building a pan-European network of clinical sites that want to maximize their involvement in clinical research with academic and industry research organizations, and create a win-win situation for industry, academic researchers, hospitals and patients.
Kortrijksesteenweg 214 b3
9830 Sint-Martens-Latem Belgium
TEL: +32 (0)9 210 78 90
TEL: +32 (0)9 210 78 90
VAT: BE 0471.970.128
BANK Acc.: 001-3437349-36
IBAN: BE46 0013 4373 4936